CN1170941C - 人bmp-7启动子以及用其探测骨相关物质的方法 - Google Patents
人bmp-7启动子以及用其探测骨相关物质的方法 Download PDFInfo
- Publication number
- CN1170941C CN1170941C CNB998079553A CN99807955A CN1170941C CN 1170941 C CN1170941 C CN 1170941C CN B998079553 A CNB998079553 A CN B998079553A CN 99807955 A CN99807955 A CN 99807955A CN 1170941 C CN1170941 C CN 1170941C
- Authority
- CN
- China
- Prior art keywords
- bone
- bmp
- dna
- related substance
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000000126 substance Substances 0.000 title claims description 18
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 title abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 20
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 15
- 208000017169 kidney disease Diseases 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 3
- 239000013604 expression vector Substances 0.000 claims description 21
- 238000003259 recombinant expression Methods 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 12
- 108091008146 restriction endonucleases Proteins 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 8
- 230000029087 digestion Effects 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000008676 import Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000002826 placenta Anatomy 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 238000001976 enzyme digestion Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 14
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 230000014509 gene expression Effects 0.000 abstract description 10
- 150000003384 small molecules Chemical class 0.000 abstract description 10
- 210000000845 cartilage Anatomy 0.000 abstract description 9
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 208000015100 cartilage disease Diseases 0.000 abstract 1
- 230000001002 morphogenetic effect Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 37
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 21
- 239000000463 material Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 108700024394 Exon Proteins 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 4
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 244000225942 Viola tricolor Species 0.000 description 3
- 235000004031 Viola x wittrockiana Nutrition 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000003360 nephrocyte Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010582 Congenital osteodystrophy Diseases 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000007652 Dysostoses Diseases 0.000 description 1
- 201000001324 Dysostosis Diseases 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 206010072970 Meniscus injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000762365 Mus musculus Bone morphogenetic protein 2 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000001909 alveolar process Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002670 chondrogenetic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供根据报道活性、使用含人BMP-7启动子的5′上游区基因和导入与适当报道基因连接的载体的动物细胞,探测正向或负向调节人BMP-7表达的低分子量化合物的方法。用本方法获得的低分子量化合物及其衍生物通过表达人BMP-7对骨和软骨具有形态发生活性或抑制活性的,并可用作软骨和骨疾病的预防或治疗药物。而且该低分子量化合物及其衍生物可用作肾脏疾病的治疗药物。
Description
发明背景
(1)发明领域
本发明涉及含人骨形成蛋白(此后称为BMP-7)启动子的5’上游区DNA。而且本发明涉及探测正向或负向调节人BMP-7表达的低分子量化合物的方法,该方法使用导入含人BMP-7启动子的5’上游区DNA、整合入适当报道基因的重组表达载体的大量动物或酵母菌细胞,并使用报道活性作为指示物。
(2)相关技术的描述
目前,已有关于属于TGF(转化生长因子)-β超家族的骨形成因子BMP的骨形成活性作了报告(Science 150,893-897,1965;Science242,1528-1534,1988)。已知的BMP种类有BMP-1至BMP-14。其中已知BMP-2至BMP-14的BMP具有骨形成活性。认为BMP-2至BMP-14的BMP对各种骨机能障碍和骨疾病的治疗和预防性治疗是有效的,然而其天然存在量很少。因此为了提供这些治疗使用的大量BMP-2至BMP-14,需要生产重组蛋白。与低分子量化合物相比,重组蛋白的生产通常非常昂贵。而且由于其蛋白质特性,重组蛋白作为药物在物理性质和给药方面存在许多限制。考虑到这些情况,如果有与所述BMP蛋白具有同等活性的小分子量有机化合物,它将成为非常有前景的药物。用本发明所提供的探测方法获得的物质具有诱导人骨形成因子BMP-7表达的活性,而且也具有与人BMP-7同样的活性。相反,如果BMP-7涉及骨和软骨增生,则抑制其表达可防止骨增生。本发明能够检测人BMP-7表达的抑制并提供探测防止增生的物质的方法。此外已知人BMP-7能促进肾细胞的分化(Proc.Natnl.Acad.Sci.,U.S.A.,第93卷,第9021-9026页,1996)。因此本发明所提供的实验系统可用于探测治疗肾脏疾病药物的方法。
对于这样的一种探测方法,至今仅有的报告是一个使用鼠BMP-2启动子实例(WO 97/15308),没有使用人BMP-7启动子的实例。此外,因为本发明所提供的探测方法中的材料均来源于人,所以可以预期所发现的物质在临床实际应用中具有效果。
发明概述
本发明提供含人BMP-7启动子的5’上游区DNA。通过使用含人BMP-7启动子的5’上游区基因和已导入与适当报道基因连接的重组表达载体的动物细胞,根据报道活性可探测正向或负向调节人BMP-7表达的低分子量化合物。该低分子量化合物及其衍生物通过表达人BMP-7对骨和软骨具有形态发生活性和抑制活性,且可用作软骨和骨疾病的有效预防或治疗药物、骨转移有效药物或过量骨形成的治疗和预防有效药物。此外,这些低分子量化合物及其衍生物可用作肾脏疾病的预防或治疗药物。
附图简述
图1是人BMP-7基因10.8kb 5’上游区外显子-内含子结构及限制性酶图,网状表示外显子区,而空方框表示内含子区。
图2是含有人BMP-7基因5’上游区的重组表达载体(pMSS115)。启动子区(4.4kb)(序列表SEQ ID NO.1所示的第3813-8222号碱基,是指在图1中从5’末端第2个XbaI到第3个XbaI)插入到pGL3-基本型的Nhe I限制性酶位点。
图3是测量人BMP-7启动子活性(瞬时表达)的结果
优选实施方案的描述
本发明涉及一种DNA,其核苷酸序列为序列表SEQ ID NO.1所示第1-10877号碱基序列,它编码人骨形成蛋白-7启动子区或其片段。序列表的SEQ ID NO.1表示人BMP-7基因5’上游区序列。
本发明涉及通过进行以下步骤制备序列表SEQ ID NO.1所示DNA的方法:
(1)用HindIII限制性酶消化人胎盘基因组DNA,
(2)通过琼脂糖凝胶电泳分离,
(3)将用HindIII消化的分离DNA片段克隆到用相同的酶处理
的λ噬菌体载体λDASHII中,
(4)将所述载体包装入噬菌体中,
(5)用噬菌体感染大肠杆菌建立基因组DNA文库,
(6)用PCR筛选,和
(7)亚克隆至质粒载体中。
这里所用的质粒载体是不受限制的,且可使用商品化质粒。pUC18载体可是优选实例。
本发明涉及一种重组表达载体,其特征为序列表SEQ ID NO.1中所示全长或部分DNA整合入报道基因中。详细地讲,重组表达载体构建是将序列表SEQ ID NO.1所示的人BMP-7基因5’上游适当区置于报道基因之前。报道基因如荧光素酶或β-半乳糖苷酶基因指示原始产物的表达状态。对于重组表达载体的原始载体不受特别限制,允许用商业化的质粒载体。本发明用pGL3-基本型作为最佳实例。使用pGL3-基本型获得的pMSS116(8.2kb)、pMSS118(7.1kb)和pMSS119(10.5kb)是含人BMP-7启动子和荧光素酶报道基因的重组表达载体。本发明将其指定为重组表达载体。必要的是用脂质体将所述重组表达载体导入哺乳动物细胞、优选人成骨细胞样细胞如SaOS-2细胞。用抗性标记选择稳定转染重组表达载体的动物细胞。
本发明涉及探测骨相关物质的方法,该方法的特征为使用序列表SEQ ID NO.1所示全长或部分DNA整合至报道基因为特点的重组表达载体。本发明涉及探测其中骨相关物质是骨形成诱导物质的骨相关物质的方法,或探测其中骨相关物质为骨形成抑制物质的骨相关物质的方法。诱导或抑制人BMP-7表达的低分子量化合物可通过以下方法获得:分离调节所述基因表达的启动子,将其与适当报道基因连接以及将所述基因结构物导入适当哺乳动物细胞以制成探测系统。在该探测系统中调节人BMP-7表达的物质作用于所述启动子以增加或降低所述报道基因的表达水平。因此简单且容易地测量所述报道活性使对所述目标物质的探测成为可能。
用所述载体转染的动物细胞可用于通过高产率筛选(Nature,第384卷(增补),第14-16页,1996)筛选化合物文库以及从天然物质中探测活性物质的方法。通过用一种物质处理所述细胞适当时间,然后测量报道活性,从而探查增加或降低活性的物质。这样获得的物质可通过调节信号转导系统直接作用于转录因子或间接作用于所述人BMP-7启动子而调节所述表达。因此这些化合物作为骨软骨病、癌性骨转移或骨质增生的治疗药物是有效的。
而且这些化合物可用作肾脏疾病的治疗药物。
本发明获得的物质具有骨或软骨形成活性,且在整形外科领域(骨折,骨关节炎如关节骨关节炎和髋关节骨关节炎,关节骨炎,软骨损伤如半月板损伤,创伤和肿瘤切除引起的骨以及软骨缺损的再生,骨再建如脊骨接合和椎管扩大,以及先天性软骨和骨疾病如骨发育障碍和软骨发育不全)或牙科领域(骨再建如腭裂、下颌骨再建和牙槽残嵴构建)和骨质疏松的治疗和预防性治疗的有效药物。而且本发明的物质可用于美容外科中的骨移植。这些治疗性治疗对在兽医外科领域中的治疗是有效的。另一方面,本发明可提供抑制骨或软骨形成的物质。在这种情况下,该物质用作骨或软骨增生的预防和治疗的药物。
另外,本发明能提供可促进肾细胞分化的物质,并可将其用作治疗和预防肾脏疾病的药物。
实施例
通过以下的实施例将对本发明作更直观的解释。以下实施例在各方面都均考虑为是说明性的,不能认是为限制性的。
实施例1 人BMP-7基因5’上游区的分离
通过使用各种限制性酶(BamHI、BglII、EcoRI、HindIII、PstI、SacI、SalI、SmaI、SphI和XbaI)消化人胎盘基因组DNA(CloneTech产品),通过琼脂糖凝胶电泳分离,转移至尼龙膜,并用BMP-7cDNA(EMBO J.9:2085-2093,1990)作探针进行DNA杂交。结果发现在所用的限制性酶中限制性酶HindIII消化产生含最长的人BMP-7基因的约11kb DNA片段。然后用限制性酶HindIII消化并用琼脂糖凝胶电泳分离人胎盘基因组DNA,从琼脂糖凝胶中提取约11kb DNA片段。将所获得的DNA片段克隆至用限制性酶HindIII消化的λ噬菌体载体λDASHII(Stratagene公司制造)。将该载体在体外用GigapackIII XL Extract(Stratagene公司制造)包装,感染至大肠肝菌XL1-Blue MRA(Stratagene公司制造)中以建立基因组DNA文库。将该DNA库划分成池(pool)。每个池用PCR筛选(Nucleic Acid Res.21:2627-2631,1993)扩增;即使用对应于翻译区的PCR引物(序列表SEQ ID NO.2和SEQ ID NO.3)的PCR方法选择目标池,最后获得人BMP-7基因5’上游区(10.8kb)。另外将5’上游10.8kb片段亚克隆至pUC 18载体(Amersham Pharmacia Biotech产品)。该载体命名为大肠杆菌pKOT 314。该大肠杆菌pKOT 314于1998年3月30日保藏在日本国立生命科学和人体技术研究所(National Institute ofBioscience and Human-Technology,Agency of Industrial Science andTechnology,Ministry of International Trade and Industry 1-3,Higash 1-chome,Tsukuba-shi Ibaraki-ken 305-8566,日本),保藏号为FERM P-16737,并于1999年2月17日转至布达佩斯条约微生物国际保藏单位,保藏号为FERM BP-6651。
实施例2 人BMP-7基因5’上游区DNA序列的测定
根据Sanger等的方法(Proc.Natl.Acad.Sci.USA 74:5463-5467,1977),用Amersham Pharmacia Biotech’s ALF DNA测序仪测定所获得的人BMP-7基因5’上游区序列。这样分析的序列描述在序列表SEQID NO.1中。已报告SEQ ID NO.1的5557-10780号碱基序列(EMBOJ.9:2085-2093,1990)。然而与本发明序列存在许多差异。
实施例3 构建含人BMP-7启动子和荧光素酶报道基因的重组表达载体。
如图1所示,人BMP-7启动子存在于外显子1上游。那么,含图1启动子(5’末端第二个XbaI至第三个XbaI)的4.4kb区域,排列在报道基因上游,将其插入荧光素酶报道载体pGL3-基本型(ProMega公司产品)的限制性酶位点NheI,从而构建重组表达载体pMSS115(9.2kb)。见图2。
实施例4 人BMP-7启动子活性的测量(将重组表达载体导入人细胞并瞬时表达)
为了瞬时表达人BMP-7重组表达载体,将所述重组表达载体(pMSS115)与含海洋三色紫罗兰荧光素酶基因的作为内对照的载体pRL-SV40(Pro Mega公司产品)混合,以测量等量基因导入的效率。然后将阳离子脂质体脂质转染胺(Lifetech Oriental公司产品)加入到所述混合溶液中,并加到人骨肉瘤细胞HOS、MG63和SaOS-2中以转染。通过Pikka Gene Dual试剂盒(Toyo Ink公司产品)测量荧火虫荧光素酶活性和海洋三色紫罗兰荧光素酶活性。结果见图3。启动子活性以荧火虫荧光素酶活性与海洋三色紫罗兰荧光素酶活性比值表示。从该结果可知序列表的SEQ ID NO.1的DNA具有启动子活性。
实施例5 将重组表达载体导入人细胞并稳定表达
为了稳定表达人BMP-7重组表达载体,将所述载体与含嘌呤霉素抗性基因的pPUR载体(CloneTech公司产品)以10∶1的比例混合,并且也与阳离子脂质体脂质体转染胺(Lifetech Oriental公司产品)混合,并加入人骨肉瘤细胞HOS中以转染。从含嘌呤霉素的培养基(Sigma公司产品)中选择导入目标基因的细胞。
实施例6 活性低分子量化合物的筛选
将所选定的建立细胞接种在96孔板中,用各种化合物文库物质处理1-3天,用细胞溶解剂(Pro Mega公司产品)溶解,并用荧光素酶分析试剂盒(Pro Mega公司产品)测量酶活性。通过这样的方法可获得诱导或抑制人BMP-7表达的各种物质。
序列表独立文本
<210>1
<223>包括外显子1区的人BMP-75,上游基因序列
<210>2
<223>克隆5’上游人BMP-7基因序列的对应于外显子1区的正向
PCR引物
<210>3
<223>克隆5’上游人BMP-7基因序列的对应于外显子1区的反向
PCR引物
序列表
<110>Hoechst Marion Roussel Ltd
<120>人BMP-7启动子以及用其探测骨相关物质的方法。
<130>英文JH98K005 PCT SEQUENCES
<140>
<141>
<150>10-120173
<151>1998-04-30
<160>3
<170>Patentln Ver.2.1
<210>1
<211>10877
<212>DNA
<213>人
<220>
<221>misc-特征
<222>(1)..(10877)
<223>包括外显子1区的人BMP-75’上游基因序列。
<400>1
aagcttggac atcagatagc tgtgtcattc atgctaactc ttattagttg ttgcatcata 60
tgtaagatga gctcaaatct gttaatcttc ccatacgatc ttttcacatg agttgggact 120
aacctgttat atttagagta atggtttacc aatggggagg gaataaagat aaaactcgaa 180
gtaaaagaaa gaatacaatt ttttaaatga ggagaaacac agtgaaggag aggagagaag 240
gaagaaaaca acagagatgg agagaagcac gacgtggggt ggtgaggagt tcccaggact 300
ctgggagcga ggagcccagt ctaatccctg attcactgta agactttggg cccagcagtt 360
tctctttggg tgtcaatttc tctatcttca agatgaagga attgaaccac gcttctgcag 420
gacttttgtt gtaactgact ggaaactccg tacacaatgg cttaaactga acagtcctgg 480
gtggggctgg cttcagggat agtgggctcc aggggctcac tgatgctgtc agtctcctgc 540
cttttcttgt tttactgtct tgtggcttct ctcacagggc aggctctccc tgaagggagg 600
gaagatgaca gccagcagca gcccctgacc tagcaacccc agtgggagga gagacccctt 660
taccggtagt tctagcaaaa gttctaaaag ttgaatctca ctggcctgga ttaggtcaca 720
tgactgtcac tgaacccatc gcatgggcat ctctggttga ccaggctggg tcatgtgccc 780
agtctgaatt ttagagaaga ggatagttca acctgaaata cagggactga tggtgaagaa 840
ggggcatttc tactgaggaa aacagaggaa atcttggcca ggcacagtgg cttatgcctg 900
taatcccagc actttgagag gccaagatgg atggattgtt tgaggcccgg agttcaagac 960
cagtctggcc agcgtggtgt aaccctgtct tctactaaaa atacaaaaat tagccaggca 1020
tggtggtgca cacctgtaat tccagctact cgggggggct gaggagggag aattgcttga 1080
aaccgggagg cagaggttac agtgagctga gattgtgcca ttgcactcca gcctgggtga 1140
cagagggaga ctctgtctaa aaaaaaaaag aaaagaaaag aaaacagagg aaatatttgc 1200
agaagaagga gaaaaggcag gggtctcaaa ttaggtgagc ttccaaagtg ttttctgtgg 1260
aaccctggga gcagagaaaa tggtagtgaa aagaaacagg cctggggact ctgggcccct 1320
gctgggatca cctgataaca ggcagggtgt ccagtccgat ttgaacttca gataaacaac 1380
gagtaaattt cagtatgagt atatataata catatactcc aatataatgg gatatagtca 1440
tactaaaatt cattcattgt ttatctgaaa ttcaaattga actggacacc tatttttttt 1500
tttgcaaaat gtggtaaccc tagtccctcc cctgctctat gtaaccaaag aagctctgtt 1560
tctgttttct gtgtcgagca tgtgtgaaaa actccttgac caaaagtttt agcgctgcac 1620
aaaagagaag gcctgtatcc ttttaactga catgattgcc atgccctctc cagctcccca 1680
gtgctgtatc cagcagggct tctggctgca ggcaacagaa accagcttgg gcaggctggt 1740
gcggaaaagg agaccactag aggatcttgg gggctcacag aacccctggg aaggccagag 1800
aaccaggctt gggggctctc tagttgggac acggccccag atcactctgc agaatagtct 1860
gggcctgcac tgatagcttc tggggtgggt gcctctgact ggctgaaact tggtcacctg 1920
tcagggctct ggctgcaaag caggctagac agtgcctctc tggatattca ccagatgggg 1980
catcctcaac cataagagag ggctcagatc tagctgggag gagggagatg ctgaaaagca 2040
ggagcaatga acactcactc ctgctcttgc agatggaatt ctggtttttg atgtttctcg 2100
ggagaggggg agtttatcag atcagtcacc agggccaaac agcagagttt tgctgggaag 2160
ggactctggg gaaggttagg gtcagatttt gcctaaaggg gcagacagtt ccagcctttt 2220
caaccactgg ctcagtagcc ctcgaatcat gaattcaatg gagctgtctt gaaatgcacc 2280
atccttggtg gtcctttggt ttgggtgatg ggttggggga ggctgggcac atcctccaga 2340
cacagcagag ccctttatga ggccaggggc aaaccagatt catcgaatct gactggtaga 2400
tgtgtcttct ttggtctaat aaccaaaacg agttgaatta gttgccaaca gataaacatt 2460
gagagatgtc acattcaaac tcaagtttct agcttctttg gaaaatcaga actttctggt 2520
gatgttggaa tcaaatttct ggatggcatc acccatgggc atgtggtttc cagttcaccc 2580
cagtctgcac cctccttatt tatccaggcc agtgtctcct gccacctgtc accatgtctg 2640
tgctcatgat tgccttccat taaattaaga ggaagagaaa tattccttga gcttcatgtt 2700
gcatctctgt atttatgtta cctggttggt gcccgttggc ttttgagtgt atgacttctg 2760
caataaagga ggaattgaag aagggctcag aggtatgttc ctcaaacact gatagggcat 2820
ctactgtgtg caaggcctcc atgggtactg ggaggtccct acaggactaa gacaaaccct 2880
gtgttttggt gtacctcaat gtttaaggac ttaagtcctg gaacaagata gccggcgtca 2940
gaattctgat tttaccattc actcaccatt ggtgtggctt tgggcaggtt ccctcaagta 3000
tttgagcctc aatttcctca tctgtaaaat ggggataata ataataaaaa tcatacaagg 3060
tagttgggag aattaatgag ttaattttaa aagacacctg gaatcataga tattgaagtt 3120
ttaatttgaa gccccaattt gtcagctata acttcagaaa tctagagcct cgatcgtcaa 3180
catacagcct gaagacgaca gcctccgagc cccccaggag ctagttagaa gtgcagaatc 3240
tcagctcact cagactgact gtgggaatct atgttctaac agacccccag gggattcaca 3300
cgcacagttg ggttggagaa gtgttgcttt aggttaaagc aaggaaggaa ggggctgctc 3360
ccaggtcact gaacgtgcac tgatgcttaa aggcctgggc tgtgtagaca gatgtggctt 3420
tggatcctgg ctccattaca gattagattg gctgtctgac tctggacaag gtgctctcgg 3480
gatgttggtc ctcctctgca atctgaggag cagaactagc ctctccatgc agtggggagt 3540
tgcgggtgat gtgggcttgg gccgtgcagg cctagcaggt gcccagcaga agcaagtgct 3600
cccaacaggt gacaggtcgg ccgctcccct gtcacgtttt ggaaggagga aagggctacc 3660
tctagtgctg aaccgaggat agttagtgct caaaaccata ccagatttcc tccaatcaag 3720
gaagaaataa cagccctgat aataataaac aaaaccactg cttcccccta gctggcttcc 3780
agatcctaga aatcctgcat ggtatcagct tctctagagt gtgtgtgtcg tctgtatttt 3840
ccatttggaa ctgtggccac tgccatgtgt acttaagact gatggaagac gtttaatctc 3900
ttattctgct gcttttaaag ttgtgcaaag aaaatctcag agtgggcaag cgtgaggagt 3960
ccaagcctcc cgtgcaatga gagatctgcg tgggaaacaa aatttcacca caggtgtgct 4020
ctaataattt cctctgcagg gtccacctct gcacacaacg attttcaagc ctgtgcagga 4080
ggcagctctt ggccctctat tccttgttgg ggttggaggt ccaggtcatc tggcctttgc 4140
caggtggtgt ggacagagag agagcagccc actggcttcc ttggctgtgc tccccaggga 4200
gcttccaggc cagctgagcc tcctctaggg cagatggatg aagatgaggt ccccacctcg 4260
ctgaacaatg tgtgtgtcag cagaattctt ttcttctttt tactgcctta gagagacatg 4320
ctgacttggt caaaatcact tcagcaagat gtgactgatg atgtaggaaa tgaaaactcc 4380
tggcccagca ctgggaggcc agcaggcgag gggcgcggac actgggaccg ggccacccga 4440
cacaataaca ccccttacaa ttccaggccg tctttcatcc aggcaaaggc ggccccaggt 4500
gtggagcaga ctggggcaga tcagattacg gtcctggagc ccagtgctgg gtgccctggc 4560
caggggaacc acaactgggg gtgtgtgggt tgggggctag ctgctgggga aatgagatag 4620
gacccaggga agtccctggg ccccagctgg cctgcagggg gcctaggcac aatgtgagga 4680
ttggaatgca gtgatgacct tttcatctct catgttccct tccacttcac tctctctttt 4740
gctctggtac ttttgctctt gctctcagag tcaggataca tctgcttttc tctgcttggc 4800
aaaaagcaga ccatcatgaa aagttttgtt gtaatttgaa actcaggagg ctttcctgtt 4860
accatatttt ccttttcatc cagatggtaa cacaataaca tttatcaagg gttttctctg 4920
tgttccaggc actgtgcaaa gccctttcca tgaattaagt tctgcaacct cacagcgatc 4980
ccagaagaca ggcgctatca gtccccccat tttacagatg ggggaactga ggtgtagaga 5040
ggttaagtcc cttgcccatg gtgcacagct ggaagagaca gagctggagt gtgaatgcgg 5100
ctgggcaggc tccagtgccc aggctacctc ctccacacaa gacttgccct cggcaatctc 5160
aaagcctttt ctggtggtgg gctcagctcc caaactggca tcggatgcac tcccagccag 5220
atatttcttg cttgccggtt ttcattcatt cattcattca ttcattcatt cattcattcg 5280
gcattcactg agggcctggt gcagtcttgg ggatgcctct cggggaggaa acagggaaaa 5340
gaaagacccc cccaccaagc atggatcaca gaaaagataa ggctaaatgg gggtttgtgg 5400
gacttcagag gaaaccttat ctcttgaggt cttggatatg aagagcatgt tgtctcttcc 5460
tcttgcatga gaaaagatgg cgtctcagag gaagggttgc tggggtgagg gatctgggag 5520
atgccttagc ttggcgcctg cacagtcagc cctcagtcaa ccggtctctt taggttttgg 5580
ctgtgcttat tactattcat tcaacaggta ctaattgagc acctgctgtg tgccaggctc 5640
agaataggct caggtgagat gcacaaagaa gggtaaacta gaatccttgc ttagacactg 5700
acggatcagt tgtttcatat gtaaattgta gcaccaagac ctgctgcccc tgcccccagc 5760
ctcacctgct tgtgaagatc cctccaaaag atttgagagt agataaaaag cagagactac 5820
tactgaagaa cagggctgct ttggctcctt attatttcag actttggaag aaaatgacct 5880
cctttttctc tactggcact ggaggtggca tagctgtccc tagcaagcca gcgctggagg 5940
gcgtgtgcag ggctggggac cgagcctggt ttctgttccc tgctctgcag gctcaagcac 6000
ttgctgttcc tccacctggg atgcctttcc ctggaaaagc ctgtctcttt cttgtctttc 6060
aggactcagg tcagtggcat ctcctccaaa aactcccctt cccaccctcc atcacctcac 6120
cctgtttatc tgcgcccccg cccccactgc ctgtcactta ttgcaggctg aagtgaccca 6180
ggctctccag ttgtacactc tcagatggac cctggacgac tgtggcactc ctgcaatttc 6240
cccagtctcc ctggggtagg attcctgctt gccaggatgc ccacctttcc ttctccctcc 6300
tgcatgtcct cctctgcctg gcttctgaat tgttcccaga gagagtgata gacaagatct 6360
gcctctcctt cagtccctga atcttattta aggctcttgc tttgcttccc tggcctggag 6420
gcggctcctt gatggagtct gccatgtggg ttcgctcatg gccatgtctt cctgcccagc 6480
atggtgcttg gccctgggac tggccacata atatctgggc caggtgcaaa attagtacgg 6540
ggcagggggt actttgttca taggtgattc agaaccacat atggtgacct cagagtagga 6600
aaccaagtgt ggggccctta agagctgggg ggccctgtac gactgtccag gttgcaggcc 6660
ccacagctcg cctcctgata tcctgtgctc catgcttgtc tgttgaagga aggagtgaat 6720
ggatgaagag caggtggtgg gggtggtttg agggccttgc tggtgggtgg gtagaggccc 6780
ctccctggca tggggctcaa gacctgttcc atcccacagc ctggggcctg tgtgtaaatg 6840
gccaggacct gcaggctggc atttttctgc tccttgcctg cctctggcct cccctttctc 6900
cacccatgtg gcccctcagg ttgccatcta gtccaaaagt ccccaaggga gacccagagg 6960
gccacttggc caaactactt ctgctccaga aaactgtaga agaccataat tctcttcccc 7020
agctctcctg ctccaggaag gacagcccca aagtgaggct tagccagagc ccctcccaga 7080
caagcgcccc cgcttcccca acctcagccc ttcccagctc atcccaaagg ccctctgggg 7140
acccactctc tcacccagcc ccaggagggg aaggagacag gatgaacttt taccccgctg 7200
ccctcactgc cactctgggt gcagtaattc ccttgagatc ccacaccggc agagggaccg 7260
gtgggttctg agtggtctgg ggactccctg tgacagcgtg catggctcgg tattgattga 7320
gggatgaatg gatgaggaga gacaggagag gaggccgatg gggaggtctc aggcacagac 7380
ccttggaggg gaagaggatg tgaagaccag cggctggctc cccaggcact gccacgagga 7440
gggctgatgg gaagccctag tggtggggct ggggtgtctg gtctcaggct gaggggtggc 7500
tggaaagata cagggccccg aagaggagga ggtgggaaga acccccccag ctcacacgca 7560
gttcacttat tcactcaaca aatcgtgact gcgcacgtac agtggctacc aggcgctggg 7620
ttcaaggcac tgcgggtacc agaggtgcgg agaagatcgc tgatccgggc cccagtgctc 7680
tgggtgtcta gcgggggtaa gaaggcaata aagaaggcac ggagtaactc aaacagcaat 7740
tccagacagc aagagaaact acaggaaaga aaacaaacgt gcgaggggcg aggcgaggaa 7800
acaacctcag cttggcaggt cttggaggtc tctgggagga gaaagcagcg tctgatgggg 7860
gcgggaggtg gtgagtgggg agaggtccag gcggagggaa tggcgagcgc agagacaggc 7920
tggcaacggc ttcagggagg cgcggagggg tcagcgtggc tggcttaaaa ggatacatgg 7980
gactgagggg caagaccggc tcaagggtca ccgcttccag gaagccttct atttccgcgc 8040
caacctcggc gctcccccaa cttttcccac cgcggtccgc agcccacccg tcctgctcgg 8100
gccgccttcc tggtccggac cgcgagtgcc gagagggcag ggccggctcc gattcctcca 8160
gccgcatccc cgcgacgtcc cgccaggctc taggcacccc gtgggcaccc agtaaacatt 8220
tgtcgagcgc tctagaggga atgaatgaac ccactgggca cagctggggg gagggcgggg 8280
ccgagggcag gtgggaggcc gccggcgcgg gaggggcccc tcgaagcccg tcctcctcct 8340
cctcctcctc cgcccaggcc ccagcgcgta ccactctggc gctcccgagg cggcctcttg 8400
tgcgatccag ggcgcacaag gctgggagag cgccccgggg cccctgctat ccgcgccgga 8460
gttggaagag ggtgggttgc cgccgcccga gggcgagagc gccagaggag cgggaagaag 8520
gagcgctcgc ccgcccgcct gcctcctcgc tgcctccccg gcgttggctc tctggactcc 8580
taggcttgct ggctgctcct cccacccgcg cccgcctcct cactcgcctt ttcgttcgcc 8640
ggggctgctt tccaagccct gcggtgcgcc cgggcgagtg cggggcgagg ggcccggggc 8700
cagcaccgag cagggggcgg gggtccgggc agagcgcggc cggccgggga ggggccatgt 8760
ctggcgcggg cgcagcgggg cccgtctgca gcaagtgacc gacggccggg acggccgcct 8820
gccccctctg ccacctgggg cggtgcgggc ccggagcccg gagcccgggt agcgcgtaga 8880
gccggcgcga tgcacgtgcg ctcactgcga gctgcggcgc cgcacagctt cgtggcgctc 8940
tgggcacccc tgttcctgct gcgctccgcc ctggccgact tcagcctgga caacgaggtg 9000
cactcgagct tcatccaccg gcgcctccgc agccaggagc ggcgggagat gcagcgcgag 9060
atcctctcca ttttgggctt gccccaccgc ccgcgcccgc acctccaggg caagcacaac 9120
tcggcaccca tgttcatgct ggacctgtac aacgccatgg cggtggagga gggcggcggg 9180
cccggcggcc agggcttctc ctacccctac aaggccgtct tcagtaccca gggcccccct 9240
ctggccagcc tgcaagatag ccatttcctc accgacgccg acatggtcat gagcttcgtc 9300
aacctcggtg agtaagggca ggcgagggta cgcgtctcct ttcgggggca ctttgagact 9360
gggagggagg gagccgcttc ttctatgcag cccgcccagc tttccgctcc tggctgaaat 9420
cgcagtgcct gcccgagggt ctcccaccca cagccctatg actcccaagc tgtgtgcgcc 9480
cccaggtcgg gcgcgctggg ttcggtgagc ctgtaggggt tactgggaag gagggatcct 9540
ccgaagtccc ctccatgtta cgccgccggc cgcatctctg gggctggagg caagggccgt 9600
tcaaagcgcg gggctcggtc atgtgagctg tcccgggccg gcgcggctcg cgtaacctgg 9660
atgtaaaggg cccttcccgg cgaggctgcc ttgccgccct tcctgggccc ctctcagccc 9720
tgcctggccc tggcatcgcg gccgtcgcac ccccttaccc tccctgtcaa gccctacctg 9780
tcccctcgtg gtgcgcccgc cttagcgtac cgcgcgctcc gagcgcttgg ggcccctctc 9840
cgggccgccg gatgccccat tctctcttgg ctggagctgg ggaagaaacg gtgccattgc 9900
taattttctt tgttttcttt ctttgtttat tttttttctt ttttcttttt ttttcttttc 9960
ttttcttttc tttttttttt ttttttgaga cggagttcac tcttgtcgcc cagtctggag 10020
tgcaatggcg cgatctctgc tcaccgcaac ctctgcctcc cgggttcaag cgattctcgt 10080
gcctcagcct cccgagtagc tgggattaca gcatgcgcca ccatgcctgg ctaattttgt 10140
atttttagta gagacagggt ttctccatgt taggcaggct ggtctcgaac tcccgatctc 10200
aggtgatcct cccgcctcag cctcccaaag tggtgctggg attacaggcg tgagccactg 10260
tgccctgccg ctagtcttct attttaagta tttagtggta ggtcccgggc cggcagaatc 10320
tattttcagc atttaccacg tgtggcgcgc aaaccacagg ttttggcgat tgggttgcgc 10380
gggatctcag actgacgcgc gggggcggct gggggtcccg gtttccgact ggagccgcga 10440
cgaccccggc gacgcgagcc tggggctgca gcgagggccg gggagctccc cctccatatg 10500
tgcgcgcaca ttctccagac ttgctcaaac taaccccccg cggcgccagc gcgctgcggg 105 60
actgatgatc aaatatttgg tttccgagat aacacacccc gatagcgctg tttcctgagc 10620
cgctttcatt ctacttgtgt aacttgctgc gaaaacccga accaagtcaa gacagcaaac 10680
tcaccccacg ggcgctgtgt caacatggaa ataatgatac tgaagcccca cgctgggcac 10740
ctggggcgtg gactgggggc gcgggggaag cgcagatccg ccttcatgct tcccccctcc 10800
tgataaggtc cctggagttc ccgggaggcc attgtctgta cttaataata actaaatcca 10860
actagtgaac caagctt 10877
<210>2
<211>30
<212>DNA
<213>人
<220>
<221>misc-特征
<222>(1)..(30)
<223>克隆5’上游人BMP-7基因序列的对应于外显子1区的正向PCR引物.
<400>2
gggcgcagcg gggcccgtct gcagcaagtg 30
<210>3
<211>30
<212>DNA
<213>人
<220>
<221>misc-特征
<222>互补物(Complement)((1)..(30))
<223>克隆5’上游人BMP-7基因序列的对应于外显子1区的反向PCR引物.
<400>3
agaggatctc gcgctgcatc tcccgccgct 30
Claims (7)
1.一种DNA,其核苷酸序列为序列表SEQ ID NO.1所示的第1-10877号碱基序列,它编码人骨形成蛋白-7启动子区。
2.一种制备序列表的SEQ ID NO.1所示DNA的方法,该方法包括以下步骤:
(1)用HindIII限制性酶消化人胎盘基因组DNA,
(2)通过琼脂糖凝胶电泳进行分离,
(3)将用HindIII消化的分离的DNA片段克隆到用同样的酶处理的λ噬菌体载体λDASH II中,
(4)将所述载体包装入所述噬菌体中
(5)用所述噬菌体感染大肠杆菌建立基因组DNA文库,
(6)用PCR进行筛选,以及
(7)亚克隆至质粒载体中。
3.一种重组表达载体,其特征为序列表的SEQ ID NO.1所示DNA的全长整合至报道基因中。
4.探测骨相关物质的方法,包括将权利要求3的重组表达载体导入哺乳动物细胞和检测报道基因活性。
5.按照权利要求4的探测骨相关物质的方法,其中所述骨相关物质是骨形成诱导物质。
6.按照权利要求4的探测骨相关物质的方法,其中所述骨相关物质是骨形成抑制物质。
7.一种探测治疗肾脏疾病的有效物质的方法,包括将按照权利要求3的重组表达载体导入哺乳动物细胞并测量报道基因活性以确定所述化合物是否存在。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10120174A JPH11313675A (ja) | 1998-04-30 | 1998-04-30 | ヒトbmp−7プロモーターおよびこれを用いた骨関連物質の探索法 |
JP120174/1998 | 1998-04-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1307643A CN1307643A (zh) | 2001-08-08 |
CN1170941C true CN1170941C (zh) | 2004-10-13 |
Family
ID=14779761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998079553A Expired - Fee Related CN1170941C (zh) | 1998-04-30 | 1999-04-22 | 人bmp-7启动子以及用其探测骨相关物质的方法 |
Country Status (26)
Country | Link |
---|---|
US (2) | US6534268B1 (zh) |
EP (1) | EP1076713A1 (zh) |
JP (1) | JPH11313675A (zh) |
KR (1) | KR20010071193A (zh) |
CN (1) | CN1170941C (zh) |
AP (1) | AP1329A (zh) |
AU (1) | AU769124B2 (zh) |
BG (1) | BG64780B1 (zh) |
BR (1) | BR9910585A (zh) |
CA (1) | CA2326957A1 (zh) |
EA (1) | EA004509B1 (zh) |
EE (1) | EE200000627A (zh) |
GE (1) | GEP20033056B (zh) |
HR (1) | HRP20000736A2 (zh) |
HU (1) | HUP0102329A3 (zh) |
ID (1) | ID26704A (zh) |
IL (1) | IL139100A0 (zh) |
NO (1) | NO20005433L (zh) |
NZ (1) | NZ507625A (zh) |
PL (1) | PL343817A1 (zh) |
SK (1) | SK16082000A3 (zh) |
TR (1) | TR200003182T2 (zh) |
UA (1) | UA72212C2 (zh) |
WO (1) | WO1999057293A1 (zh) |
YU (1) | YU64900A (zh) |
ZA (1) | ZA200006080B (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040225077A1 (en) | 2002-12-30 | 2004-11-11 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US20070015701A1 (en) * | 2005-06-01 | 2007-01-18 | Samuel Zalipsky | Macromolecular conjugates of bone morphogenetic protein-7 |
PL2078073T3 (pl) * | 2006-10-12 | 2013-12-31 | Ethicon Inc | Komórki pochodzące z nerki oraz sposoby ich zastosowania w leczeniu i regeneracji tkanki |
CA2681317C (en) * | 2008-05-16 | 2013-04-02 | Industry Foundation Of Chonnam National University | A synthetic peptide containing bone forming peptide 1(bfp 1) for stimulating osteoblast differentiation, and pharmaceutical composition comprising the synthetic peptide |
WO2011156590A2 (en) | 2010-06-09 | 2011-12-15 | Semprus Biosciences Corp. | Non-fouling, anti-microbial, anti-thrombogenic graft compositions |
EP2579907A4 (en) | 2010-06-09 | 2016-03-23 | Arrow Int Inc | ARTICLES HAVING NON-FORMING SURFACES AND PREPARATION METHODS COMPRISING THE PRIMARY LAYER APPLICATION |
JP6083071B2 (ja) | 2010-06-09 | 2017-02-22 | アロー インターナショナル インコーポレイテッド | 非汚染性、抗菌性、抗血栓性グラフトフロム組成物 |
CA2808655C (en) | 2010-08-18 | 2019-11-26 | Emory University | Compounds and compositions for ossification and methods related thereto |
WO2012116137A2 (en) | 2011-02-24 | 2012-08-30 | Emory University | Jab1 blocking compositions for ossification and methods related thereto |
CA2827392A1 (en) | 2011-02-24 | 2012-08-30 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
AU2012351980B2 (en) | 2011-12-14 | 2015-09-17 | Arrow International, Inc. | Silicone hydrogel contact lens modified using Lanthanide or Transition metal oxidants |
MX2014007204A (es) | 2011-12-14 | 2015-04-14 | Semprus Biosciences Corp | Proceso de uv de multietapas para crear lentes de contacto modificadas en la superficie. |
CA2858730C (en) | 2011-12-14 | 2017-07-18 | Semprus Biosciences Corp. | Surface modified contact lenses |
AU2012368232B2 (en) | 2011-12-14 | 2016-01-07 | Arrow International, Inc. | Imbibing process for contact lens surface modification |
JP2015507761A (ja) | 2011-12-14 | 2015-03-12 | センプラス・バイオサイエンシーズ・コーポレイションSemprus Biosciences Corp. | コンタクトレンズ改質のためのレドックス法 |
WO2019005563A1 (en) * | 2017-06-27 | 2019-01-03 | St. Jude Children's Research Hospital | METHODS ASSOCIATED WITH THE ACTIVATION OF THE SIGNALING PATHWAY OF BONE MORPHOGENETIC PROTEINS |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990011366A1 (en) * | 1989-03-28 | 1990-10-04 | Genetics Institute, Inc. | Osteoinductive compositions |
US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
US5650276A (en) * | 1991-03-11 | 1997-07-22 | Creative Biomolecules, Inc. | Morphogenic protein screening method |
AU2407192A (en) * | 1991-08-01 | 1993-03-02 | Pharmaceutical Discovery Corporation | Characterization of specific drug receptors with fluorescent ligands |
EP0804573A1 (en) | 1994-06-07 | 1997-11-05 | Creative Biomolecules, Inc. | Methods and compositions for modulating morphogenic protein expression |
US6083690A (en) * | 1995-06-02 | 2000-07-04 | Osteoscreen, Inc. | Methods and compositions for identifying osteogenic agents |
JP2001509010A (ja) | 1996-11-22 | 2001-07-10 | アクゾ・ノベル・エヌ・ベー | Bmp―4プロモーターならびに骨粗鬆症の予防および/または治療用の治療剤のスクリーニングにおけるその用途 |
US5863790A (en) | 1997-05-14 | 1999-01-26 | Minnesota Mining And Manfacturing Company | Biological sterility indicator |
WO1998054344A2 (en) * | 1997-05-29 | 1998-12-03 | Creative Biomolecules, Inc. | Modulators of morphogen expression and methods of identifying the same |
-
1998
- 1998-04-30 JP JP10120174A patent/JPH11313675A/ja active Pending
-
1999
- 1999-04-22 CA CA002326957A patent/CA2326957A1/en not_active Abandoned
- 1999-04-22 AU AU31634/99A patent/AU769124B2/en not_active Ceased
- 1999-04-22 EA EA200001130A patent/EA004509B1/ru not_active IP Right Cessation
- 1999-04-22 SK SK1608-2000A patent/SK16082000A3/sk unknown
- 1999-04-22 NZ NZ507625A patent/NZ507625A/en unknown
- 1999-04-22 IL IL13910099A patent/IL139100A0/xx unknown
- 1999-04-22 EE EEP200000627A patent/EE200000627A/xx unknown
- 1999-04-22 TR TR2000/03182T patent/TR200003182T2/xx unknown
- 1999-04-22 GE GEAP19995635A patent/GEP20033056B/en unknown
- 1999-04-22 WO PCT/IB1999/000733 patent/WO1999057293A1/en not_active Application Discontinuation
- 1999-04-22 CN CNB998079553A patent/CN1170941C/zh not_active Expired - Fee Related
- 1999-04-22 HU HU0102329A patent/HUP0102329A3/hu unknown
- 1999-04-22 AP APAP/P/2000/001982A patent/AP1329A/en active
- 1999-04-22 BR BR9910585-3A patent/BR9910585A/pt not_active IP Right Cessation
- 1999-04-22 ID IDW20002196A patent/ID26704A/id unknown
- 1999-04-22 KR KR1020007012054A patent/KR20010071193A/ko not_active Application Discontinuation
- 1999-04-22 UA UA2000116830A patent/UA72212C2/uk unknown
- 1999-04-22 PL PL99343817A patent/PL343817A1/xx not_active Application Discontinuation
- 1999-04-22 YU YU64900A patent/YU64900A/sh unknown
- 1999-04-22 EP EP99913528A patent/EP1076713A1/en not_active Withdrawn
- 1999-04-22 US US09/674,311 patent/US6534268B1/en not_active Expired - Fee Related
-
2000
- 2000-10-24 BG BG104883A patent/BG64780B1/bg unknown
- 2000-10-27 NO NO20005433A patent/NO20005433L/no not_active Application Discontinuation
- 2000-10-27 ZA ZA200006080A patent/ZA200006080B/xx unknown
- 2000-10-30 HR HR20000736A patent/HRP20000736A2/hr not_active Application Discontinuation
-
2002
- 2002-10-03 US US10/263,788 patent/US20030040007A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HRP20000736A2 (en) | 2001-10-31 |
US20030040007A1 (en) | 2003-02-27 |
JPH11313675A (ja) | 1999-11-16 |
HUP0102329A3 (en) | 2006-03-28 |
CN1307643A (zh) | 2001-08-08 |
AU769124B2 (en) | 2004-01-15 |
HUP0102329A2 (hu) | 2001-10-28 |
US6534268B1 (en) | 2003-03-18 |
BG104883A (en) | 2001-05-31 |
AP2000001982A0 (en) | 2000-12-31 |
CA2326957A1 (en) | 1999-11-11 |
NZ507625A (en) | 2003-12-19 |
GEP20033056B (en) | 2003-08-25 |
TR200003182T2 (tr) | 2001-02-21 |
AP1329A (en) | 2004-11-22 |
PL343817A1 (en) | 2001-09-10 |
EA004509B1 (ru) | 2004-04-29 |
IL139100A0 (en) | 2001-11-25 |
NO20005433D0 (no) | 2000-10-27 |
ZA200006080B (en) | 2001-10-29 |
WO1999057293A1 (en) | 1999-11-11 |
NO20005433L (no) | 2000-10-27 |
SK16082000A3 (sk) | 2001-05-10 |
YU64900A (sh) | 2003-10-31 |
ID26704A (id) | 2001-02-01 |
EA200001130A1 (ru) | 2001-04-23 |
EE200000627A (et) | 2002-02-15 |
AU3163499A (en) | 1999-11-23 |
UA72212C2 (en) | 2005-02-15 |
EP1076713A1 (en) | 2001-02-21 |
BR9910585A (pt) | 2001-01-09 |
BG64780B1 (bg) | 2006-03-31 |
KR20010071193A (ko) | 2001-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1170941C (zh) | 人bmp-7启动子以及用其探测骨相关物质的方法 | |
CN1283793C (zh) | 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族 | |
CN1932016A (zh) | 影响sre活性的多核苷酸及其编码多肽和用途 | |
CN1244595C (zh) | 一种肿瘤抑制蛋白及其应用 | |
CN1160370C (zh) | 新的人细胞周期控制相关蛋白及其编码序列 | |
CN1194012C (zh) | 精子生成相关蛋白、其编码序列及用途 | |
CN1273600C (zh) | 红豆杉紫杉烷c13-侧链-n-苯甲酰转运酶蛋白及其编码基因 | |
CN1600861A (zh) | 棉花乙烯响应元件绑定因子蛋白编码序列 | |
CN1563386A (zh) | 棉花甲硫氨酸亚砜还原酶蛋白编码序列 | |
CN1177864C (zh) | 在肝癌组织中具有表达差异的新的人蛋白及其编码序列 | |
CN1232642C (zh) | 炎性抑制因子Fwa116 | |
CN1179974C (zh) | 植物耐逆相关的信号传递基因及其编码的蛋白质 | |
CN1252270C (zh) | 红豆杉3-羟基-3-甲基戊二酰辅酶a合成酶蛋白编码序列 | |
CN1277844C (zh) | 新型人细胞周期蛋白,其编码序列及用途 | |
CN1491281A (zh) | 神经调节素及其应用 | |
CN1584032A (zh) | 甘蓝型油菜细胞分裂原激活的蛋白激酶3蛋白编码序列 | |
CN1243017C (zh) | 肿瘤抑制基因及其编码蛋白和应用 | |
CN1213069C (zh) | 发育促进因子、其制法及用途 | |
CN1549857A (zh) | 睾丸肉碱转运蛋白及其基因 | |
CN1594570A (zh) | 甘蓝型油菜细胞分裂原激活的蛋白激酶的激酶1蛋白编码序列 | |
CN1169833C (zh) | 具有抑癌功能的新的人蛋白及其编码序列 | |
CN1155613C (zh) | 人类17号染色体短臂1区3带3亚带区域内人肿瘤相关基因和编码蛋白 | |
CN1528889A (zh) | 大白菜9-顺式-环氧类胡萝卜素双氧酶蛋白编码序列 | |
CN1199999C (zh) | 具有促进3t3细胞转化功能的新的人蛋白及其编码序列 | |
CN1304568C (zh) | 新型人补体C1r样丝氨酸蛋白酶类似物,其编码序列及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: VENTIS PHARMA S.A. Free format text: FORMER NAME OR ADDRESS: HOECHST MARION ROUSSEL INC. |
|
CP03 | Change of name, title or address |
Address after: French Anthony Patentee after: Aventis Pharma Address before: French AUX Patentee before: Hoechst Marion Roussel |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |